SG11201900681SA - Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors - Google Patents
Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitorsInfo
- Publication number
- SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- hyderabad
- serene
- life sciences
- avenue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028166 | 2016-08-18 | ||
| PCT/IB2017/054938 WO2018033847A1 (fr) | 2016-08-18 | 2017-08-14 | Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900681SA true SG11201900681SA (en) | 2019-02-27 |
Family
ID=59887325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900681SA SG11201900681SA (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10603323B2 (fr) |
| EP (1) | EP3500253B1 (fr) |
| JP (1) | JP6734470B2 (fr) |
| KR (1) | KR102039585B1 (fr) |
| CN (1) | CN109640975B (fr) |
| AU (1) | AU2017313427B2 (fr) |
| BR (1) | BR112019002645A2 (fr) |
| CA (1) | CA3033039C (fr) |
| CY (1) | CY1123238T1 (fr) |
| DK (1) | DK3500253T3 (fr) |
| EA (1) | EA032957B1 (fr) |
| ES (1) | ES2810983T3 (fr) |
| HR (1) | HRP20201262T1 (fr) |
| HU (1) | HUE052003T2 (fr) |
| IL (1) | IL264406B (fr) |
| LT (1) | LT3500253T (fr) |
| MA (1) | MA45990B1 (fr) |
| MD (1) | MD3500253T2 (fr) |
| ME (1) | ME03812B (fr) |
| MX (1) | MX2019001696A (fr) |
| NZ (1) | NZ750150A (fr) |
| PL (1) | PL3500253T3 (fr) |
| PT (1) | PT3500253T (fr) |
| RS (1) | RS60669B1 (fr) |
| SG (1) | SG11201900681SA (fr) |
| SI (1) | SI3500253T1 (fr) |
| WO (1) | WO2018033847A1 (fr) |
| ZA (1) | ZA201900467B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52850A (fr) * | 2018-05-31 | 2021-04-21 | Suven Life Sciences Ltd | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120077802A1 (en) * | 2009-06-10 | 2012-03-29 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| DK2694492T3 (en) * | 2011-02-23 | 2015-11-09 | Suven Life Sciences Ltd | NOVEL COMPOUNDS AS HISTAMINE H3 receptor ligands |
| FR2974729B1 (fr) | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| SG11201601306QA (en) | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2017
- 2017-08-14 ES ES17768234T patent/ES2810983T3/es active Active
- 2017-08-14 DK DK17768234.1T patent/DK3500253T3/da active
- 2017-08-14 BR BR112019002645A patent/BR112019002645A2/pt active Search and Examination
- 2017-08-14 PT PT177682341T patent/PT3500253T/pt unknown
- 2017-08-14 AU AU2017313427A patent/AU2017313427B2/en active Active
- 2017-08-14 CA CA3033039A patent/CA3033039C/fr active Active
- 2017-08-14 HU HUE17768234A patent/HUE052003T2/hu unknown
- 2017-08-14 JP JP2019506640A patent/JP6734470B2/ja active Active
- 2017-08-14 RS RS20200949A patent/RS60669B1/sr unknown
- 2017-08-14 EP EP17768234.1A patent/EP3500253B1/fr active Active
- 2017-08-14 EA EA201990480A patent/EA032957B1/ru unknown
- 2017-08-14 MD MDE20190714T patent/MD3500253T2/ro unknown
- 2017-08-14 SG SG11201900681SA patent/SG11201900681SA/en unknown
- 2017-08-14 ME MEP-2020-167A patent/ME03812B/fr unknown
- 2017-08-14 MA MA45990A patent/MA45990B1/fr unknown
- 2017-08-14 MX MX2019001696A patent/MX2019001696A/es active IP Right Grant
- 2017-08-14 KR KR1020197007056A patent/KR102039585B1/ko active IP Right Grant
- 2017-08-14 US US16/320,949 patent/US10603323B2/en active Active
- 2017-08-14 SI SI201730360T patent/SI3500253T1/sl unknown
- 2017-08-14 PL PL17768234T patent/PL3500253T3/pl unknown
- 2017-08-14 WO PCT/IB2017/054938 patent/WO2018033847A1/fr active Search and Examination
- 2017-08-14 LT LTEP17768234.1T patent/LT3500253T/lt unknown
- 2017-08-14 NZ NZ750150A patent/NZ750150A/en unknown
- 2017-08-14 CN CN201780049311.9A patent/CN109640975B/zh active Active
-
2019
- 2019-01-22 IL IL264406A patent/IL264406B/en active IP Right Grant
- 2019-01-23 ZA ZA2019/00467A patent/ZA201900467B/en unknown
-
2020
- 2020-08-05 CY CY20201100725T patent/CY1123238T1/el unknown
- 2020-08-11 HR HRP20201262TT patent/HRP20201262T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201900269XA (en) | Channel sensing for independent links | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |